FIRST EXTENSION - GRANTED
granted
on 07 Oct 2024
Last Applicant/ Owned by
201 Tresser Boulevard
Stamford
CT
06901
Serial Number
97132159 filed on 18th Nov 2021
Registration Number
N/A
Correspondent Address
FARA S. SUNDERJI
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
K KNOA PHARMA
Pharmaceutical research and development A house mark for a full line of pharmaceuticals; pharmaceuticals for use in the treatment of central nervous system disorders, pain, opioid overdose, opioid reversal, opioid use disorders, interstitial cystitis/bladder pain syndrome (IC/BPS), Overactive Bladder (OAB), Alcohol Use Disorder, Substance Use Disorder, sleep disorders including Insomnia Associate Read More
Classification Information
Class [042]
Computer & Software Services & Scientific Services
Pharmaceutical research and development
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [005]
Pharmaceutical Products
A house mark for a full line of pharmaceuticals; pharmaceuticals for use in the treatment of central nervous system disorders, pain, opioid overdose, opioid reversal, opioid use disorders, interstitial cystitis/bladder pain syndrome (IC/BPS), Overactive Bladder (OAB), Alcohol Use Disorder, Substance Use Disorder, sleep disorders including Insomnia Associated with Alcohol Cessation (IAAC), anaphylaxis; pharmaceuticals for use in the treatment of oncology conditions, specifically glioblastoma multiforme (GBM), non Hodgkin lymphoma, solid tumors, melanoma, chronic myelogenous leukemia, hemato-oncology, refractory/relapsed malignancies, alone or in combination with other agents; analgesics; pharmaceuticals, namely, opioid antagonists; syringes filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; syringes filled with opioid antagonists; injectors filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; injectors filled with opioid antagonists; injectable pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; injectable pharmaceuticals, namely, opioid antagonists
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 97132159
Mark Type
No Service Mark
Attorney Docket Number
No
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 07th Oct 2024 | SOU EXTENSION 1 FILED |
| 07th Oct 2024 | SOU EXTENSION 1 GRANTED |
| 07th Oct 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 07th Oct 2024 | SOU TEAS EXTENSION RECEIVED |
| 04th Jun 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| 12th Apr 2024 | OPPOSITION TERMINATED NO. 999999 |
| 12th Apr 2024 | TTAB RELEASE CASE TO TRADEMARKS |
| 12th Apr 2024 | OPPOSITION DISMISSED NO. 999999 |
| 01st Jun 2023 | OPPOSITION INSTITUTED NO. 999999 |
| 01st Jun 2023 | OPPOSITION PAPERS RECEIVED AT TTAB |